Project List
List projects.
Fields
id (integer)
Primary key.
Expansions
To activate relation expansion add the desired fields as a comma separated
list to the expand query parameter like this:
?expand=<field>,<field>,<field>,...
The following relational fields can be expanded:
organizationcategorytypepartner_functionmanagercontactstatusgrantresearcheventstudylanguageprogramfunders
Filters
To filter for exact value matches:
?<fieldname>=<value>
Possible exact filters:
organizationcategorymanagercontactstatusgrantresearchstudylanguagefundersprogram
For advanced filtering use lookups:
?<fieldname>__<lookup>=<value>
All fields with advanced lookups can also be used for exact value matches as described above.
Possible advanced lookups:
begin_planned:gt,gte,lt,ltebegin_effective:gt,gte,lt,lteend_planned:gt,gte,lt,lteend_effective:gt,gte,lt,lte
GET /v1/research/project/?format=api&offset=320&ordering=-end_effective
{ "count": 2329, "next": "https://api-test.medunigraz.at/v1/research/project/?format=api&limit=20&offset=340&ordering=-end_effective", "previous": "https://api-test.medunigraz.at/v1/research/project/?format=api&limit=20&offset=300&ordering=-end_effective", "results": [ { "id": 6760, "title": { "de": "Apolipoprotein AI(apo-AI) Peptid-Lipid Komplexe", "en": "Apolipoprotein AI(apo-AI) Mimetic Peptide Lipid Assemblies" }, "short": "AAMLA", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2022-01-01T01:00:00+01:00", "begin_effective": "2022-01-01T01:00:00+01:00", "end_planned": "2025-12-31T01:00:00+01:00", "end_effective": "2026-11-30T01:00:00+01:00", "assignment": "2021-10-22T11:40:29+02:00", "program": 111, "subprogram": null, "organization": 14011, "category": 10, "type": 10, "partner_function": 3, "manager": 83104, "contact": null, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 9 ], "funder_projectcode": "I5703", "ethics_committee": null, "edudract_number": null, "persons": [ "6760-83104-10", "6760-83104-12", "6760-107231-12" ] }, { "id": 8530, "title": { "de": "Krebsbekämpfung mit digitaler Pathologie ", "en": "Fighting cancer with digital pathology " }, "short": null, "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2024-12-01T01:00:00+01:00", "begin_effective": "2024-12-01T01:00:00+01:00", "end_planned": "2026-11-30T01:00:00+01:00", "end_effective": "2026-11-30T01:00:00+01:00", "assignment": "2024-11-26T10:47:29+01:00", "program": 206, "subprogram": null, "organization": 14047, "category": 10, "type": 10, "partner_function": 4, "manager": 92422, "contact": null, "status": 2, "research": 10, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 20 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "8530-92422-10" ] }, { "id": 6787, "title": { "de": "Apolipoprotein AI (apo-AI) Mimetische \r\nPeptid-Lipid-Assemblies", "en": "Apolipoprotein AI (apo-AI) Mimetic \r\nPeptide Lipid Assemblies" }, "short": "AAMLA", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2022-01-01T01:00:00+01:00", "begin_effective": "2022-01-01T01:00:00+01:00", "end_planned": "2025-12-31T01:00:00+01:00", "end_effective": "2026-11-30T01:00:00+01:00", "assignment": "2021-11-17T15:51:22+01:00", "program": 111, "subprogram": null, "organization": 14022, "category": 10, "type": 10, "partner_function": 2, "manager": 53252, "contact": null, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 9 ], "funder_projectcode": "I5703", "ethics_committee": null, "edudract_number": null, "persons": [ "6787-53252-10" ] }, { "id": 9486, "title": { "de": "Gezielte Nanopartikel-Therapie zur Entzündungshemmung bei Sepsis", "en": "Targeted nanoparticle therapy for inflammation reduction in sepsis" }, "short": "nanoparticle therapy_sepsis", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2025-12-01T01:00:00+01:00", "begin_effective": "2025-12-01T01:00:00+01:00", "end_planned": "2026-05-31T02:00:00+02:00", "end_effective": "2026-11-30T01:00:00+01:00", "assignment": "2025-12-15T11:33:07+01:00", "program": null, "subprogram": null, "organization": 14022, "category": 10, "type": 10, "partner_function": 4, "manager": 111769, "contact": null, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 457 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "9486-111769-10" ] }, { "id": 7906, "title": { "de": "INTERACT-EUROPE 100", "en": "INTERACT-EUROPE 100" }, "short": "INTERACT", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2024-01-01T01:00:00+01:00", "begin_effective": "2023-12-01T01:00:00+01:00", "end_planned": "2026-01-01T01:00:00+01:00", "end_effective": "2026-11-30T01:00:00+01:00", "assignment": "2023-11-28T13:37:15+01:00", "program": null, "subprogram": null, "organization": 14085, "category": 10, "type": 10, "partner_function": 4, "manager": 107132, "contact": null, "status": 2, "research": 10, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 10 ], "funder_projectcode": "101129375", "ethics_committee": null, "edudract_number": null, "persons": [ "7906-107132-10" ] }, { "id": 7238, "title": { "de": "Lebensverlängerung durch [Ca2+]mito-induzierte ROS", "en": "Promotion of lifespan by mitochondrial Ca2+-induced ROS" }, "short": null, "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2022-12-01T01:00:00+01:00", "begin_effective": "2022-12-01T01:00:00+01:00", "end_planned": "2026-11-30T01:00:00+01:00", "end_effective": "2026-11-30T01:00:00+01:00", "assignment": "2022-10-31T13:29:37+01:00", "program": 72, "subprogram": null, "organization": 14013, "category": 10, "type": 10, "partner_function": 4, "manager": 85069, "contact": null, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 9 ], "funder_projectcode": "P36591", "ethics_committee": null, "edudract_number": null, "persons": [ "7238-85069-10", "7238-93963-12", "7238-111432-12", "7238-112109-12", "7238-116510-12", "7238-117501-12", "7238-121350-12", "7238-119167-12" ] }, { "id": 8591, "title": { "de": "Krebsbekämpfung mit digitaler Pathologie ", "en": "Fighting cancer with digital pathology" }, "short": null, "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2024-09-01T02:00:00+02:00", "begin_effective": "2024-12-01T01:00:00+01:00", "end_planned": "2026-08-31T02:00:00+02:00", "end_effective": "2026-11-30T01:00:00+01:00", "assignment": "2025-01-14T13:06:19+01:00", "program": 206, "subprogram": null, "organization": 14020, "category": 10, "type": 10, "partner_function": 4, "manager": 104839, "contact": null, "status": 2, "research": 2, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 20 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "8591-104839-10" ] }, { "id": 9530, "title": { "de": "Räumliche Charakterisierung von Immunzellen in den pulmonalen Arterien\r\nbei COPD- und Lungenfibrose-assoziierter pulmonaler Hypertonie", "en": "Spatial Characterization of Immune Cells in Pulmonary Arteries in COPD- and Pulmonary Fibrosis-Associated Pulmonary Hypertension" }, "short": "Spatial Characteriz_pulmon_hypertension", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2025-11-15T01:00:00+01:00", "begin_effective": "2025-11-15T01:00:00+01:00", "end_planned": "2026-11-14T01:00:00+01:00", "end_effective": "2026-11-14T01:00:00+01:00", "assignment": "2026-01-15T16:28:36+01:00", "program": null, "subprogram": null, "organization": 14006, "category": 10, "type": 10, "partner_function": 4, "manager": 97528, "contact": null, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 2471 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "9530-97528-10" ] }, { "id": 8268, "title": { "de": "Standardisierte elektronische Erfassung der Beschwerden und der Lebensqualität von Patienten/Innen mit Kopf/Hals Karzinom unter laufender Radiochemotherapie", "en": "Standardized electronic symptom and quality of life tracking of patients with head and neck cancer during radiotherapy." }, "short": "QOLHNC", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2021-11-01T01:00:00+01:00", "begin_effective": "2021-11-01T01:00:00+01:00", "end_planned": "2026-11-01T01:00:00+01:00", "end_effective": "2026-11-01T01:00:00+01:00", "assignment": "2024-06-19T15:15:36+02:00", "program": null, "subprogram": null, "organization": 14066, "category": 10, "type": 10, "partner_function": 3, "manager": 57935, "contact": null, "status": 2, "research": 2, "grant": 10, "event": null, "study": null, "language": null, "funders": [], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "8268-57935-10" ] }, { "id": 7089, "title": { "de": "Identifizierung und Entwicklung neuartiger Darmkrebs-Biomarker durch modernste Flüssigbiopsie\r\nAnsätze", "en": "Identification and development of novel colorectal cancer biomarkers via state-of-the-art liquid biopsy approaches" }, "short": "ColoMARK ", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2022-10-01T02:00:00+02:00", "begin_effective": "2022-11-01T01:00:00+01:00", "end_planned": "2026-09-30T02:00:00+02:00", "end_effective": "2026-10-31T01:00:00+01:00", "assignment": "2022-07-08T13:20:20+02:00", "program": 209, "subprogram": null, "organization": 14021, "category": 10, "type": 10, "partner_function": 2, "manager": 50899, "contact": null, "status": 2, "research": 2, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 10 ], "funder_projectcode": "101072448", "ethics_committee": null, "edudract_number": null, "persons": [ "7089-50899-10", "7089-104199-12" ] }, { "id": 9696, "title": { "de": "Establishing experimental models to study TRPC3 in neurodevelopmental disorders", "en": "Establishing experimental models to study TRPC3 in neurodevelopmental disorders" }, "short": null, "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2026-04-01T02:00:00+02:00", "begin_effective": "2026-04-01T02:00:00+02:00", "end_planned": "2026-10-01T02:00:00+02:00", "end_effective": "2026-10-31T01:00:00+01:00", "assignment": "2026-03-20T14:29:51+01:00", "program": null, "subprogram": null, "organization": 14011, "category": 10, "type": 10, "partner_function": 1, "manager": 90337, "contact": null, "status": 2, "research": 2, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 135 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "9696-90337-10" ] }, { "id": 6518, "title": { "de": "Entwicklung von interaktiven adaptierbaren und visulisierten qualitativ hochwertigen Gesundheitsinformationen ", "en": "Human-Centered Interactive Adaptive Visual\r\nApproaches in High-Quality Health Information" }, "short": null, "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2021-01-01T01:00:00+01:00", "begin_effective": "2021-05-01T02:00:00+02:00", "end_planned": "2025-12-30T01:00:00+01:00", "end_effective": "2026-10-31T01:00:00+01:00", "assignment": "2021-04-08T14:18:36+02:00", "program": 113, "subprogram": null, "organization": 27964, "category": 10, "type": 10, "partner_function": 2, "manager": 51098, "contact": null, "status": 2, "research": 5, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 9 ], "funder_projectcode": "FG 11-B", "ethics_committee": null, "edudract_number": null, "persons": [ "6518-51098-10" ] }, { "id": 7055, "title": { "de": "Lösung des offenen Rätsels von TRPC3 durch Photopharmakologie", "en": "Resolving the open state enigma of TRPC3 by photopharmacology" }, "short": null, "url": null, "abstract": { "de": "• Wider research context / theoretical framework: TRPC3 is a distinct member of TRPC family. This channel is expressed in excitable and non-excitable cells. By non-selectively conducting cations even at its resting state, TRPC3 promotes cellular processes in both health and disease. However, there are only a few modulators of this channel available. To precisely design new therapeutic ligands, it is of high importance to gain knowledge about TRPC3 protein structure and, consequently, its gating mechanism. Recently, two TRPC3 structures were revealed by cryo electron microscopy (cryo-EM). Nonetheless, neither of them captured open pore architecture. Hence, the open conformations is the critical missing piece of information to solve the TRPC3 gating puzzle. This knowledge is essential for comprehension of the molecular function of TRPC3 and definition of possible ligand binding sites to control this channel is health and, especially, disease.\r\n• Hypotheses / research questions / objectives: Here, we propose to succeed in capturing open pore structures of TRPC3 by stabilizing and synchronizing the channels at a high open probability using photochromic ligands and in addition by preserving their lipid environment during the protein preparation for cryo-EM.\r\n• Approach / methods: We will screen two expression systems for suitability to maintain TRPC3 in open conformation. We will utilize photopharmacological tools for a temporal control over TRPC3 gating during protein extraction and cryo-EM. Structural details obtained from cryo-EM will be followed by structure-guided mutagenesis and evaluated in a multifunctional live cell approach combining Ca2+ imaging and electrophysiology.\r\n• Level of originality / innovation: With our project, we will introduce a novel approach to control protein conformations during cryo-EM by photoswitchable ligands. Our work will unravel TRPC3 open architecture and promote the development of new concepts for therapeutic targeting of these channels.\r\n• Primary researchers involved: The research team will include profound experts in TRPC3 electrophysiology and Ca2+ signaling Dr. Oleksandra Tiapko and Dr. Klaus Groschner (Medical University of Graz, Austria), experts in membrane lipids Dr. Anita Emmerstorfer-Augustin (Graz University of Technology) and in structural biology and electron microscopy Dr. Christine Ziegler (University of Regensburg).", "en": "• Wider research context / theoretical framework: TRPC3 is a distinct member of TRPC family. This channel is expressed in excitable and non-excitable cells. By non-selectively conducting cations even at its resting state, TRPC3 promotes cellular processes in both health and disease. However, there are only a few modulators of this channel available. To precisely design new therapeutic ligands, it is of high importance to gain knowledge about TRPC3 protein structure and, consequently, its gating mechanism. Recently, two TRPC3 structures were revealed by cryo electron microscopy (cryo-EM). Nonetheless, neither of them captured open pore architecture. Hence, the open conformations is the critical missing piece of information to solve the TRPC3 gating puzzle. This knowledge is essential for comprehension of the molecular function of TRPC3 and definition of possible ligand binding sites to control this channel is health and, especially, disease.\r\n• Hypotheses / research questions / objectives: Here, we propose to succeed in capturing open pore structures of TRPC3 by stabilizing and synchronizing the channels at a high open probability using photochromic ligands and in addition by preserving their lipid environment during the protein preparation for cryo-EM.\r\n• Approach / methods: We will screen two expression systems for suitability to maintain TRPC3 in open conformation. We will utilize photopharmacological tools for a temporal control over TRPC3 gating during protein extraction and cryo-EM. Structural details obtained from cryo-EM will be followed by structure-guided mutagenesis and evaluated in a multifunctional live cell approach combining Ca2+ imaging and electrophysiology.\r\n• Level of originality / innovation: With our project, we will introduce a novel approach to control protein conformations during cryo-EM by photoswitchable ligands. Our work will unravel TRPC3 open architecture and promote the development of new concepts for therapeutic targeting of these channels.\r\n• Primary researchers involved: The research team will include profound experts in TRPC3 electrophysiology and Ca2+ signaling Dr. Oleksandra Tiapko and Dr. Klaus Groschner (Medical University of Graz, Austria), experts in membrane lipids Dr. Anita Emmerstorfer-Augustin (Graz University of Technology) and in structural biology and electron microscopy Dr. Christine Ziegler (University of Regensburg)." }, "begin_planned": "2022-01-01T01:00:00+01:00", "begin_effective": "2022-01-01T01:00:00+01:00", "end_planned": "2025-12-31T01:00:00+01:00", "end_effective": "2026-10-31T01:00:00+01:00", "assignment": "2022-06-13T15:55:42+02:00", "program": 72, "subprogram": null, "organization": 14011, "category": 10, "type": 10, "partner_function": 4, "manager": 90337, "contact": null, "status": 2, "research": 2, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 9 ], "funder_projectcode": " P 35291", "ethics_committee": null, "edudract_number": null, "persons": [ "7055-90337-10", "7055-116421-12" ] }, { "id": 9701, "title": { "de": "Magnetische Zustandsänderungen von Partikelagglomeraten in biologischen Systemen", "en": "Magnetically Driven Collective States of Nanoparticles in Biological Flow" }, "short": "MAGFLOW", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2026-04-01T02:00:00+02:00", "begin_effective": "2026-04-01T02:00:00+02:00", "end_planned": "2026-09-30T02:00:00+02:00", "end_effective": "2026-10-31T01:00:00+01:00", "assignment": "2026-03-23T15:26:44+01:00", "program": null, "subprogram": null, "organization": 14012, "category": 10, "type": 10, "partner_function": 4, "manager": 113130, "contact": null, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 135 ], "funder_projectcode": "PN 2016", "ethics_committee": null, "edudract_number": null, "persons": [ "9701-113130-10" ] }, { "id": 9700, "title": { "de": "Erweiterung des druggable Proteoms: Modulierung intrinsisch ungeordneter Proteine mittels integrativer Strukturbiologie ", "en": "Expanding the Druggable Proteome: Targeting Disordered Proteins via Integrative Structural Biology" }, "short": "ExPro", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2026-04-01T02:00:00+02:00", "begin_effective": "2026-04-01T02:00:00+02:00", "end_planned": "2026-10-31T01:00:00+01:00", "end_effective": "2026-10-31T01:00:00+01:00", "assignment": "2026-03-23T15:22:33+01:00", "program": null, "subprogram": null, "organization": 14012, "category": 10, "type": 10, "partner_function": 4, "manager": 137654, "contact": null, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 135 ], "funder_projectcode": "PN 2017", "ethics_committee": null, "edudract_number": null, "persons": [ "9700-137654-10" ] }, { "id": 7008, "title": { "de": "Positive Umwelteinflüsse auf die Darm-Gehirn Achse", "en": "ENVIRONMENTAL MODULATION OF GUT-BRAIN AXIS SIGNALLING" }, "short": null, "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2022-05-01T02:00:00+02:00", "begin_effective": "2022-10-01T02:00:00+02:00", "end_planned": "2025-05-01T02:00:00+02:00", "end_effective": "2026-10-31T01:00:00+01:00", "assignment": "2022-05-04T10:46:10+02:00", "program": 72, "subprogram": null, "organization": 14022, "category": 10, "type": 10, "partner_function": 4, "manager": 71386, "contact": null, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 9 ], "funder_projectcode": "P35774", "ethics_committee": null, "edudract_number": null, "persons": [ "7008-71386-10" ] }, { "id": 9748, "title": { "de": "Aufklärung von Herkunft und Schicksal von Fibroblasten und aberranten basaloiden Zellen in der idiopathischen Lungenfibrose", "en": "Lineagetracing of fibroblasts and aberrant basaloid cells in idiopathic pulmonary fibrosis" }, "short": "Fibroblasten_idiopath Lungenfibrose", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2026-03-01T01:00:00+01:00", "begin_effective": "2026-04-01T02:00:00+02:00", "end_planned": "2026-10-30T01:00:00+01:00", "end_effective": "2026-10-30T01:00:00+01:00", "assignment": "2026-04-28T16:00:19+02:00", "program": null, "subprogram": null, "organization": 14022, "category": 10, "type": 10, "partner_function": 4, "manager": 85658, "contact": null, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 135 ], "funder_projectcode": "PN 2011", "ethics_committee": null, "edudract_number": null, "persons": [ "9748-85658-10" ] }, { "id": 7490, "title": { "de": "NR4A1 mediierte Regulation der Immuneevasion in Lymphomen", "en": "NR4A1-mediated regulation of immune evasion in lymphoma*" }, "short": "NIEL", "url": null, "abstract": { "de": "Tumorzellen haben eine Reihe von Mechanismen entwickelt, um die immunvermittelte Erkennung und Zerstörung von Tumorzellen zu umgehen bzw. zu unterdrücken. Eine unserer Erkenntnisse ist, dass ein Teil der aggressiven B-Lymphome, maligne Tumore der antikörperproduzierenden Zellen, eine geringe Expression des Transkriptionsfaktors NR4A1 aufweisen. NR4A1 reguliert, wie andere Transkriptionsfaktoren, zahlreiche biologische Prozesse in Zellen. Die Funktion in aggressiven B-Lymphomen ist jedoch bis dato noch nicht untersucht worden. In unserer Vorstudie haben wir herausgefunden, dass eine niedrige NR4A1-Expression mit einer reduzierten Überlebensrate bei Standardtherapie einherging. In unserem Lymphommausmodell konnten wir nachweisen, dass der Verlust von Nr4a1 die Lymphomentwicklung deutlich beschleunigte, begleitet von einer erhöhten Expression immunsuppressiver Oberflächenmoleküle und einem höheren Gehalt an Immunzellen in Mäusen, die ein funktionierendes Immunsystem besaßen, aber nicht in Mausmodellen mit einem nicht funktionierenden Immunsystem. Weitere Analysen deuten darauf hin, dass der Verlust von Nr4a1 mit einer verminderten immunzellvermittelten Zerstörung von Lymphomzellen verbunden ist. Zusammenfassend deuten unsere Daten auf eine tumorsuppressive Funktion von NR4A1 hin, die durch immunregulatorische Eigenschaften bei der Entwicklung aggressiver Lymphome vermittelt wird.\r\nIn dem geplanten Projekt wollen wir mit globalen genetischen Ansätzen aufklären, welche Gene und/oder genetischen Programme durch NR4A1 reguliert werden, sowie mit Hilfe neuartiger Sequenzierungstechnologien die Auswirkungen von NR4A1 auf die Zusammensetzung und die Aktivität der Immunzellen in aggressiven Lymphomen untersuchen. Darüber hinaus wollen wir die Wirksamkeit von Immuntherapien als Einzelwirkstoffe sowie in Kombination (einschließlich neuer Moleküle) in Bezug auf die NR4A1-Expression bei aggressiven Lymphomen funktionell testen. Schließlich werden wir die Daten aus dem präklinischen Modell auf Patientenproben übertragen. Hier werden wir NR4A1, Antigenpräsentation und immunsuppressive Oberflächenmoleküle in unserer DLBCL-Patientenkohorte untersuchen, um unsere Erkenntnisse in einem klinischeren Umfeld zu validieren.\r\nAnhand der Ergebnisse könnten wir einen neuen Mechanismus identifizieren, der wesentlich zur Lymphomentwicklung beiträgt und zur Identifizierung von Lymphompatienten genutzt werden kann, die von einer neuartigen Immuntherapie profitieren könnten.\r\n", "en": "Tumour cells have developed a number of mechanisms to avoid or suppress their recognition, targeting and killing by immune cells. We found out that a part of aggressive B cell lymphomas, a tumour consisting of the antibody-producing cells, exhibited low expression of the transcription factor NR4A1. NR4A1, like other transcription factors, regulates numerous biological processes in cells. However, its function has not been yet investigated in aggressive B cell lymphomas. In our preliminary study, we observed that low NR4A1 levelwas associated with reduced survival in patients treated with standard therapy. In mice with a functional immune system, we showed that loss of Nr4a1 markedly accelerated the development of lymphoma, with increased presence of surface molecules that inhibit immune cells, but also a higher content of these immune cells compared to immunodeficient mouse models. Further, our analyses indicate that loss of Nr4a1 is linked to reduced killing of lymphoma by immune cells. Taken together our data indicate a tumour-suppressive function of NR4A1 mediated by its immune regulatory properties in the development of aggressive lymphomas.\r\nIn the planned project, we aim to elucidate which genes and/or genetic programs are regulated by NR4A1 with global genetic approaches and to investigate the impact of NR4A1 on immune cell composition and activity in aggressive lymphomas using novel sequencing technologies. In addition, our aim is to functionally test the efficacy of immune therapies as single agents as well as in combination (including novel molecules) in relation to the NR4A1 level in aggressive lymphomas. Finally, we will transfer data from the preclinical model to patients samples and investigate NR4A1 expression, antigen presentation, and immune suppressive surface molecules in our DLBCL patient cohort to validate our findings in a more clinical setting.\r\nBased on the finding, we might identify a novel mechanism, which significantly contribute to lymphoma development and which can be used to identify lymphoma patients who may benefit from a novel type of immune therapy. \r\n" }, "begin_planned": "2023-01-01T01:00:00+01:00", "begin_effective": "2023-05-15T02:00:00+02:00", "end_planned": "2025-12-31T01:00:00+01:00", "end_effective": "2026-10-14T02:00:00+02:00", "assignment": "2023-04-11T15:10:20+02:00", "program": null, "subprogram": null, "organization": 14082, "category": 10, "type": 10, "partner_function": 4, "manager": 59183, "contact": null, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 9 ], "funder_projectcode": "P36643", "ethics_committee": null, "edudract_number": null, "persons": [ "7490-100134-12", "7490-59183-10", "7490-79614-12", "7490-82501-12", "7490-85928-12", "7490-111069-12", "7490-130555-12", "7490-131900-12", "7490-122350-12", "7490-122590-12" ] }, { "id": 9538, "title": { "de": "Charakterisierung von Biglykans Rolle im vaskulären Umbau und der pulmonalen arteriellen Hypertonie - Ein neuer therapeutischer Angriffspunkt?", "en": "Characterization of biglycans role in vascular remodelling and pulmonary\r\narterial hypertension – A new therapeutic target?" }, "short": "BiPAH", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2025-10-06T02:00:00+02:00", "begin_effective": "2025-10-06T02:00:00+02:00", "end_planned": "2026-10-05T02:00:00+02:00", "end_effective": "2026-10-05T02:00:00+02:00", "assignment": "2026-01-19T15:12:52+01:00", "program": null, "subprogram": null, "organization": 14006, "category": 10, "type": 10, "partner_function": 3, "manager": 114963, "contact": null, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 2471 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "9538-114963-10" ] }, { "id": 9092, "title": { "de": "Gezielte elektrische Feldstimulation als neue Therapiemethode für Glioblastom Tumore", "en": "Targeted electrical field stimulation as a new therapeutic method for glioblastoma" }, "short": "GBM-Stim", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2025-07-01T02:00:00+02:00", "begin_effective": "2025-07-01T02:00:00+02:00", "end_planned": "2026-06-30T02:00:00+02:00", "end_effective": "2026-09-30T02:00:00+02:00", "assignment": "2025-07-23T12:54:09+02:00", "program": null, "subprogram": null, "organization": 14011, "category": 10, "type": 10, "partner_function": 4, "manager": 104218, "contact": null, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 135 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "9092-104218-10" ] } ] }